Overall, the NSG-SGM3 model with a humanized immune system recapitulated the observations in SM1 murine melanoma model supporting HDAC6 inhibitor-treated M1 macrophages as a potential cell therapy to treat solid tumors. This evidence concerns the gene HDAC6 and melanoma.